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Abstract 
Telomerase reverse transcriptase (TERT) is a key component of the telomerase 
complex. By lengthening telomeres in DNA strands, TERT increases senescent cell 
lifespan. Mice that lack TERT age much faster and exhibit age-related conditions such 
as osteoporosis, diabetes and neurodegeneration. Accelerated telomere shortening in 
both human and animal models has been documented in conditions associated with 
insulin resistance, including T2DM. We investigated the role of TERT, in regulating 
cellular glucose utilisation by using the myoblastoma cell line C2C12, as well as 
primary mouse and human skeletal muscle cells. Inhibition of TERT expression or 
activity by using siRNA (100 nM) or specific inhibitors (100 nM) reduced basal 2-
deoxyglucose uptake by ~50%, in all cell types, without altering insulin 
responsiveness. In contrast, TERT over-expression increased glucose uptake by 
3.25-fold. In C2C12 cells TERT protein was mostly localised intracellularly and 
stimulation of cells with insulin induced translocation to the plasma membrane. 
Furthermore, co-immunoprecipitation experiments in C2C12 cells showed that TERT 
was constitutively associated with glucose transporters (GLUTs) 1, 4 and 12 via an 
insulin insensitive interaction that also did not require intact PI3-K and mTOR 
pathways. Collectively, these findings identified a novel extra-nuclear function of TERT 
that regulates an insulin-insensitive pathway involved in glucose uptake in human and 
mouse skeletal muscle cells. 
 
  
1. Introduction 
Ageing is an established risk factor for the development of the metabolic syndrome 
and type 2 diabetes (T2DM). At the cellular level, senescence and ageing are 
associated with a decrease in telomere length and accelerated telomere shortening 
has been documented in conditions associated with insulin resistance, including T2DM 
[1–3]. Maintenance of telomere length is dependent on the activity of the enzyme 
telomerase and in particular its catalytic protein TERT (telomerase reverse 
transcriptase), which can help reverse this process and extend the lifespan of cells 
[4,5]. Models of metabolic disorders have provided further evidence for a role of TERT 
in glucose metabolism; for example, mononuclear cells of diabetic patients display 
accelerated telomere shortening in comparison to age-matched healthy individuals, 
an effect correlated with poor glycaemic control [6,7]. Furthermore telomere shortening 
in the β-cells of mice has also been found to impair insulin secretion thus leading to 
glucose intolerance even though there was an intact number of β-cell numbers, and 
so demonstrating a role of telomeres in the pathogenesis of diabetes [8]. 
In cells TERT shuttles between the nucleus and the cytoplasm[9–11]. Nuclear TERT 
regulates telomere length by catalysing addition of repetitive tandem (TTAGGG) DNA 
sequences to telomeres, thereby monitoring cell turnover and maintaining telomere 
length [12–14]. Recently TERT has been identified in mitochondria [10], where it 
appears to protect mitochondrial DNA and function from damage induced by oxidative 
stress, thus preventing apoptosis and promoting cell survival [11, 15–17]. 
Since mitochondrial function is closely associated with cellular fuel selection, we 
hypothesised that extra-nuclear functions of TERT may target the signalling pathways 
controlling glucose utilisation [18,19]. Previous in vivo studies showed that telomerase 
deficiency impairs glucose metabolism and insulin secretion [20]. The availability of 
glucose itself has also been shown to have a direct effect on the epigenetic modulation 
of TERT, resulting in the modulation of cell lifespan [21]. In addition, TERT possesses 
a consensus sequence on Ser824 for phosphorylation by Akt, which leads to 
increased activity [22–24], whereas inhibition of PI3K activity reduces both TERT 
phosphorylation by Akt and nuclear translocation, resulting in decreased nuclear 
telomerase activity [25,26]. This raises the possibility that insulin may acutely affect 
the cytosolic functions of TERT. 
Therefore, in the present study we investigated basal and insulin stimulated glucose 
uptake activity in cells with altered TERT expression or activity using mouse muscle-
derived C2C12 as well as human and primary mouse skeletal muscle cells. In addition, 
we have studied the intracellular distribution of TERT protein in response to insulin in 
C2C12 cells. We find that basal but not insulin-stimulated glucose uptake requires 
adequate TERT expression and identified a novel interaction between TERT and the 
glucose transporters GLUT1, 4 and 12. 
 
2. Materials and methods 
 
2.1. Ethics statement 
The experimental protocols for the animals were in accordance with the United 
Kingdom Animal (Scientific Procedures) Act of 1986 (ASPA). A Home Office project 
licence was not required for this study because no regulated procedures were carried 
out. Mice were humanely sacrificed by CO2 asphyxiation, which is an appropriate 
method under Schedule 1 of the Act. 
 
2.2. Cell culture 
 
2.2.1. C2C12 
The C2C12 mouse myoblast cells (American Type Culture Collection, ATCC) were 
maintained in DMEM (Invitrogen, Paisley, UK) supplemented with 5 mM glucose and 
10% FCS (BioSera, Sussex, UK) at 37 °C in 5% CO2. 
 
2.2.2. Human skeletal muscle cells 
The human skeletal muscle cells (PromoCell, UK Human Cell Culture Systems)were 
cultured in skeletal muscle growth medium provided by the supplier supplemented 
with 5% FCS, fetuin (50 μg/ml), basic fibroblast factor (1 ng/ml), epidermal growth 
factor (10 ng/ml), insulin (10 μg/ml) and dexamethasone (0.4 μg/ml) at 37 °C in 5% 
CO2. 
 
2.2.3. Primary mouse skeletal muscle cells 
The primary mouse skeletal muscle cells were isolated from 3– 7week oldmale BLaC6 
mice. Mice were sacrificed, and the gastrocnemius and soleus muscles were pooled, 
cut along the fibres and digested for 25 min at 37 °C in oxygenated collagenase (1.5 
mg/ml, Worthington Biochemicals, Lorne Laboratories, Reading, UK) solution. Cells 
were isolated as previously described [27], and kept in DMEM supplemented with 5 
mM glucose, 5% FCS and 1% penicillin/streptomycin solution (Sigma Aldrich, Dorset, 
UK) at 37 °C in 5% CO2. 
 
2.3. Pharmacological inhibitors 
TERT activity was inhibited using several pharmacologically active agents, namely 
triethylene tetraamine (TETA, Fisher Scientific, Loughborough, UK), geldanamycin 
(GA, Alexis Biochemicals, Enzo Life Sciences, Exeter, UK) and 17-(allylamino)-17-
demethoxygeldanamycin (17-AAG, Sigma Aldrich). On the day of treatment, the 
required agents were added to the cell culture medium at various concentration(s) (1–
100 nM; unless otherwise stated). Cells were incubated with the inhibitors for 1–24 h 
prior to measurement of the biological effect(s). 
 
2.4. Transfection of cells with TERT and siRNA 
The TERT-pBABE-puro construct was kindly provided by Dr Woody E. Wright 
(University of Texas). Pre-designed siRNA for human and mouse TERT was obtained 
from Dharmacon (Thermo Scientific, Loughborough, UK). Cells were subcultured into 
12-well culture plates for 24 h prior to transfection with increasing concentrations of 
either TERT plasmid or 50–500 nM siRNA using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer's instructions. Empty pBABE-puro construct and 
scrambled siRNA (Ambion Applied Biosystems, Warrington, UK) were used as 
controls. During the optimisation phase of the methodology, significant reduction of 
cell viability was observed when the concentration of siRNA heteroduplexes exceeded 
200 nM (data not shown) and for that reason a concentration of 100 nM siRNA was 
employed in all subsequent experiments. 
 
2.5. 2-Deoxyglucose uptake assay 
2-Deoxyglucose uptake measurements were carried out as described previously, for 
10 min in glucose-free DMEM supplemented with 0.1% BSA containing 20 μM 2-[3H]-
deoxy-D-glucose (0.53 μCi/ml, AmershamGE Health, Buckinghamshire, UK) in the 
absence or presence of insulin and inhibitors, unless otherwise stated [28]. Non-carrier 
mediated uptake was determined in parallel in the presence of 10 μM cytochalasin B 
(Alexis Biochemicals) and the values subtracted from the total uptake per assay.  
 
2.6. Immunofluorescence staining and confocal microscopy 
Cells were grown on cover-slips and treated as required. They were subsequently 
fixed using 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 and blocked 
for 1 h in 5% goat serum and BSA. Cells were stained with anti-TERT antibody (1:200, 
Novus Biologicals, Cambridge, UK), anti-GLUT1 (1:100, Abcam, Cambridge, UK), 
anti- GLUT4 (1:100, Abcam) and anti-GLUT12 (1:100 [29]) and detected using (1:400) 
AlexaFluor® 488 goat anti-rabbit fluorescent secondary antibody (Invitrogen). 
Samples were mounted in media containing DAPI (Vector Labs, Peterborough, UK). 
Negative controls were run with secondary antibody alone to exclude any non-specific 
binding/ autofluorescence. Images were acquired with an AxioVert 200M laser 
scanning confocal microscope under either a 20 × x or 40–63 × 1.4 NA oil immersion 
objective. Images were captured using a Carl Zeiss laser scanning microscope and 
LSM 510 imaging software. Fluorescence intensity profiles were generated along 
multiple line axes, analysed, and quantified using ImageJ software developed at the 
National Institutes of Health (http://rsb.info.nih.gov/ij/). Quantification was carried out 
on thirty cells from randomly chosen fields (n= 3) for each condition. Both paired region 
of analysis and region of interest were used to monitor changes in protein intracellular 
distribution. 
 
2.7. Western blotting 
Cell protein extracts were resolved by SDS-PAGE (10%). The proteins were 
transferred onto nitrocellulose membrane and immunoblotted with the appropriate 
antibody and detected using chemiluminescence substrate (SuperSignalWest Pico, 
Thermo Scientific, UK).  
 
2.8. Immunoprecipitation 
Cells were lysed in ice-cold lysis buffer (20 mM HEPES, 500 mM NaCl, 25 mM DTT, 
20% glycerol and 0.1% NP-40, and supplemented with 1:100 protease and 
phosphatase inhibitor cocktails). The extracts were incubated with each antibody and 
15 μl of protein G-beads (Millipore, Watford, UK), and the immunoprecipitates 
subjected to SDS-PAGE. To ensure use of equal amounts of protein per sample, blots 
were performed before immunoprecipitation experiments using β-actin (data not 
shown). 
 
2.9. Statistical analysis 
Values are represented as the means±SEM, for the number of independent 
experiments indicated in the legends of the figures. Data were tested for homogeneity 
and comparison between group means was performed by two-tailed Student's t-test 
with Prism software (v. 5.03, GraphPad Software). Significant difference among 
different treatment groups was denoted by p b 0.05. 
 
3. Results 
3.1. Expression characteristics of TERT in C2C12 
In preliminary experiments we investigated the expression and subcellular localisation 
characteristics of TERT in C2C12 myoblasts. Using RT-PCR we detected significant 
levels of TERT mRNA; furthermore these cells express a protein with a molecular 
mass of 120 kDa recognized by a specific TERT antibody (data not shown).We also 
used indirect immunofluorescent signal detection by confocal microscopy to 
investigate TERT expression characteristics. As previously described [30], in cells 
such as R-cells (L5178Y murine lymphoma cell line) that possess very long telomeres 
(~48 kb), TERT is highly expressed and exclusively localised in the nucleus. By 
contrast, in C2C12 cells, we detected a different expression pattern; under 
unstimulated conditions, basal TERT immunostaining was distributed diffusely 
throughout the cytoplasm with only weak signal in the nucleus, raising the possibility 
of extra-nuclear actions of TERT in these cells (Fig. 1a).  
C2C12 cells respond to insulin actions via an extensive signalling network that 
involves activation of the PI3-K and mTOR signalling cascades [31–34]. Exposure of 
C2C12 cells to insulin (100nMfor 1 h) induced TERT intracellular movement evident 
from increased TERT signal redistribution near or at the plasma membrane by 35% 
(Fig. 1b). Similar experiments were repeated in C2C12 cells engineered to 
overexpress exogenous TERT (C2C12-TERT). These cells expressed 5–7 fold higher 
levels of TERT compared to native C2C12 cells (data not shown) and 
immunofluorescent signal detection showed that plasmid transfection resulted in a 
significant increase in TERT signal without any changes in subcellular localisation 
characteristics with the majority of the intracellular signal detected in the cytoplasm 
but not the nucleus (Fig. 1c). Exposing these cells to insulin led in a 2-fold increase in 
TERT signal translocated near or at the plasma membrane compared to control 
untreated cells. Insulin actions required intact PI3-K and mTOR activity since pre-
treatment of C2C12-TERT cells with either wortmannin or rapamycin abolished insulin 
effect on TERT translocation (Fig. 1d). 
 
3.2. TERT co-localises with GLUTs in C2C12 cells 
The insulin-regulated localisation of TERT in C2C12 prompted us to study potential 
interactions between TERT and GLUTs, which represent major targets of insulin in the 
control of glucose uptake by skeletal muscle cells. Preliminary RT-PCR experiments 
using sequence-specific primers for GLUT1, GLUT4 and GLUT12 amplified DNA 
fragments for each GLUT in both undifferentiated and differentiated C2C12 myoblasts 
(Fig. 2a). Moreover, immunostaining experiments using specific antibodies detected 
strong immunofluorescent signal for each of the three GLUTs in C2C12 cells (Fig. 2b). 
Similar to other cell types [35–37], the housekeeping transporter GLUT1 signal was 
detected in both cytoplasm and plasma membrane, whereas GLUT4 and GLUT12 
staining was primarily in the cytoplasm. Insulin treatment of C2C12 cells led to 
significant redistribution of GLUT4 and GLUT12 signal; however although GLUT4 
signal showed the expected translocation to the cell surface, GLUT12 signal was 
localised to peri-nuclear structures that were also stained by an antibody against a 
Golgi marker (Fig. 2b).  
The possibility of direct interaction between TERT and GLUTs was further investigated 
in C2C12 cells. Co-immunoprecipitation studies with an anti-TERT antibody in whole 
cell extracts identified a constitutive association between TERT and all three glucose 
transporters (GLUT1, GLUT4 and GLUT12). Under insulin stimulated conditions, 
TERT association with GLUT12 but not GLUTs 1 and 4 was enhanced by insulin 
stimulation. However, basal or insulin-induced interaction appeared to be independent 
of PI3-K and mTOR activity since pretreatment of cells with either wortmannin or 
rapamycin had no effect on TERT–GLUT associations (Fig. 3). In addition, TETA a 
telomerase inhibitor did not affect TERT association with GLUT1, GLUT4 and 
GLUT12. Interestingly, exposure of C2C12 cells to geldanamycin (which inhibits TERT 
through inhibition of the hsp90–TERT complex formation) appeared to reduce the 
amount of GLUT12 co-immunoprecipitated by the TERT antibody, without altering 
immunoprecipitated GLUT1 and GLUT4 levels. 
 
3.3. TERT and 2-deoxyglucose (2-DG) uptake in C2C12 
The studies described above raised the possibility that TERT is involved in the 
regulation of glucose uptake in skeletal muscle cells. This was investigated in C2C12 
myoblasts by a 2-DG uptake assay; unstimulated cells exhibited significant 2-DG 
uptake (71 ± 5 pmol/ 10 min/mg protein). In agreement with previous studies [36] 
treatment with insulin (100nM) for 10minsignificantly increased 2-DGuptake by 44% 
compared to non-treated cells. To test the effect of TERT on basal glucose uptake, we 
employed knock-down of TERT expression by short interfering RNA sequences 
complementary to the TERT transcript.. Preliminary experiments (Fig. 4a) 
demonstrated that at a concentration of 100 nM, specific siRNA effectively reduced 
TERT mRNA expression by 40–50% and protein by 80–90% in C2C12 cells. In 
contrast, transfection of cells with random sequence siRNA had no effect on TERT 
expression.  
Knock-down of TERT expression in the C2C12 cells using siRNA resulted in a 
significant reduction in basal 2-DG uptake by approximately 20% (Fig. 4b). The 
difference in the efficiency of the siRNA to down-regulate mRNA and protein 
expression may reflect the manner in which siRNA targets mRNA and interferes with 
its degradation and therefore the impact on the linked but independent gene 
transcription and subsequent protein translation could be quite different. Cell viability 
assays confirmed that this inhibitory effect did not result from increased cell death (Fig. 
4c). Using a complementary approach we also investigated the effects of TERT 
inhibitors; all inhibitors tested (geldanamycin, 17-AAG and TETA) significantly 
decreased basal 2-DG uptake in C2C12 cells by varying degrees of potency of 32–
71%. Interestingly, we also observed inhibitory effects between 27 and 55% of these 
compounds on TERT mRNA expression raising the possibility that their action might 
involve regulation of TERT transcription (Fig. 4d). The inhibitory effects of siRNA or 
chemical TERT inhibitors were not due to non-specific toxic effects of these inhibitors 
as both cell viability (Fig. 4c) and total cell protein remained unchanged.  
Follow-up experiments investigated also the effect of TERT overexpression on basal 
2-DG uptake in C2C12-TERT cells. In these cells, increased intracellular TERT 
expression led to a 53% increase in basal 2-DG uptake (Fig. 5).  
Since our previous experiments identified insulin-dependent regulation of TERT 
intracellular localisation, we next investigated whether TERT was involved in insulin 
induced glucose transport. Although maximal stimulation was attenuated in TERT 
inhibitor-treated cells, insulin effect on 2-DG uptake was comparable between TERT 
inhibitor treated and control cells (Fig. 6a) suggesting that TERT inhibition does not 
affect the ability of insulin to stimulate glucose transport. Moreover, insulin effects were 
not affected by TERT knocked-down or overexpression (data not shown) confirming 
independence from TERT expression levels.  
To investigate whether TERT effects were cell type specific, we carried out similar 
experiments in primary mouse skeletal muscle cells and in human muscle cells. In 
both types of cells overexpression of TERT increased basal 2-DG uptake by 3–3.5 
fold but did not affect the magnitude of insulin responses, suggesting a similar mode 
of TERT actions in these cells (Fig. 6b). Moreover, silencing TERT mRNA expression 
by siRNA in both human and primary mouse skeletal muscle cells reduced the basal 
rate of glucose uptake by 37% and 43% respectively (Fig. 6c), but did not alter insulin 
effects (data not shown). 
 
4. Discussion 
The present work identified a novel extra-nuclear function of TERT that contributes in 
the regulation of basal glucose transport in C2C12 myoblasts. Similar findings in 
human and primary mouse skeletal muscle cells provide further support for the 
physiological relevance of TERT actions. Muscle cells take up ~65% of the glucose 
produced by the liver in the basal, low-insulin concentration, and are responsible for 
80% of the insulin-stimulated glucose disposal. To exert this action skeletal muscle 
TERT is primarily localised outside the nucleus, in the cytoplasm and its subcellular 
localisation and trafficking to the cell surface appear to be regulated by the insulin 
signalling machinery, in particular the mTOR and PI3-K cascades. At present the 
functional consequences of TERT–insulin interactions are unknown but our studies 
suggest that it is unlikely to involve regulation of insulin-induced glucose uptake, a 
mechanism which is not affected by changes in TERT expression. 
One potential mechanism that would allow TERT to regulate basal glucose uptake 
might involve protein–protein interactions with the various glucose transporters, which 
contributes to basal as well as extracellular signal-stimulated glucose uptake, such as 
the GLUT1, GLUT4 and GLUT12, as indicated by their co-immunoprecipitation with 
TERT in unstimulated C2C12 cells. TERT–GLUT interaction appears to be 
independent of insulin signalling mediators such as mTOR and PI3-K activity. To date, 
several GLUT-binding proteins have been identified [36], including aldolase and α-
actinin 4 which may work as scaffolds linking GLUT to actin cytoskeleton or other 
specific intracellular anchors such as: Ubc 9, the sentrin-conjugated enzyme, 
predicted to regulate GLUT4 and GLUT1 protein turnover; Daxx, the adapter protein 
associated with Fas; and the type II TGF-β receptors, which also binds GLUT4 (but 
not GLUT1) and may lead to GLUT4 SUMOlation. Interactions of these proteins with 
GLUT C-terminus are also found to occur independent of insulin. Other GLUT partners 
such as the aminopeptidase IRAP might regulate endosomal retention and regulate 
exocytosis of GLUTs in the unstimulated state, either through static or dynamic 
retention within endosomes, therefore TERT might play similar regulatory roles in 
C2C12 cells. 
The physiological significance of these findings may reside in the changes that occur 
in TERT expression during ageing and cell senescence. TERT activity decreases with 
age, resulting in telomere shortening. It is well-established that impaired telomerase 
activity (and accompanying reduction in telomere length) is strongly associated with 
the process of ageing and senescence. In this context, it may be relevant that in 
various models accelerated telomere shortening is also associated with insulin 
resistance and type-2 diabetes [6–8]. Similarly, ageing is linked to increased insulin 
resistance of which one of the main metabolic characteristics of muscle is its loss of 
its ability to up-regulate glucose uptake in response to insulin. Therefore, loss of TERT 
activity (e.g. in diabetes, ageing) and insulin sensitivity of glucose uptake might occur 
in parallel. Our observations may point towards a potential link as TERT interacts with 
the molecular machinery controlling glucose uptake. Our data may explain why 
conditions of diminished TERT expression (associated with accelerated telomere 
shortening) may also adversely affect glucose transport.  
In conclusion, the present data identified a novel extra-nuclear function of TERT 
mediated via association of TERT with GLUT proteins to regulate glucose transport. 
Further studies will now focus on the precise interactions of TERT with the insulin 
signalling cascade. These findings might provide clues and possible mechanistic 
information for the diminished insulin-responsiveness, with ageing, of glucose uptake 
by muscle cells. 
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Figure Legends: 
 
Fig. 1. Confocal micrographs of C2C12 cells immunostained for endogenous TERT 
protein and in the presence of insulin, wortmannin and rapamycin. a) C2C12 and R 
cells were immunostained for endogenous TERT using an Alexa-Fluor® 488 (green) 
secondary antibody. b) C2C12 cells treated with 100 nM insulin for 1 h and 
immunostained for endogenous TERT protein. c) C2C12 cells were transfected with 2 
μg TERT plasmid and subsequently treated with 100 nM insulin for 10 min alone or 
with 100 nM wortmannin or rapamycin for 1 h and then insulin for 10 min and after 24 
h immunostained for TERT protein. Cell nuclei were respectively stained with DAPI 
(blue) and images captured using confocal microscopy (C2C12 cells at 63× objective). 
Micrographs are representative of three separate experiments. d) 30 random cells per 
treatment (n= 3) were processed using ImageJ, where the total fluorescent intensity 
and change in protein distribution were determined by measuring paired regions of 
interest. Images were analysed for changes in protein localisation between the 
nucleus and cytoplasm by defining a cross-sectional area and plotting profiles of 
fluorescent intensity across that area. Data is representative for fluorescent intensities 
averaged from 30 random cells (n= 3). Values presented are mean (±SEM) of 3 
independent experiments. Asterisks indicate statistical significance (t-test) of 
difference from control samples: **p b 0.01 and ***p b 0.001. 
 
Fig. 2. Glucose transporter 1, 4 and 12 mRNA expression in C2C12 and confocal 
micrographs of C2C12 cells showing immunostaining of GLUT1, 4 and 12 in the 
presence and absence of insulin. a) Graphs show the mRNA expression of GLUTs 1, 
4 and 12 in undifferentiated (U) and differentiated (D) C2C12 cells. Reverse 
transcription PCR (RT-PCR) was performed on RNA extracted from treated cells. 
GAPDH mRNA was used as an internal control and an image of the gel was captured 
and used to quantify GLUT mRNA expression using ImageJ software. C2C12 cells 
immunostained for endogenous b) GLUT1, GLUT4 and GLUT12 proteins. Cells were 
treated with 100 nM insulin for 1 h and immunostained. Cells were imaged using an 
Alexa-Fluor® 488 (green) secondary antibody. Cell nuclei were respectively stained 
with DAPI (blue) and images captured using confocal microscopy. Micrographs are 
representative of three separate experiments. Images were analysed for changes in 
protein localisation between the nucleus and cytoplasm by defining a cross-sectional 
area and plotting profiles of fluorescent intensity across that area. 
 
Fig. 3. Association of TERT protein with GLUT1, GLUT4 and GLUT12 proteins in 
C2C12 cells and the effect of inhibitors on this interaction. C2C12 cell lysates were 
immunoprecipitated with TERT antibody and probed for GLUT1, GLUT4 and GLUT12 
proteins in control cells and in cells incubated with 100 nM insulin. C2C12 cell lysates 
were prepared from control cells and cells treated with 100 nM rapamycin (for 24 h), 
wortmannin (1 h), geldanamycin or TETA (24 h). 20 μg of each cell lysate was 
immunoprecipitated with TERT antibody and probed for GLUT1, GLUT4 and GLUT12 
proteins. Protein G beads were used as a control. β-Actin probing before IPwas used 
as a loading control. Results are representative of three independent experiments (IP: 
immunoprecipitation and WB: western blotted). 
 
Fig. 4. Effect of TERT siRNA and inhibitors on [3H] 2-deoxyglucose uptake and TERT 
mRNA and protein expression in C2C12 cells. The effect of TERT siRNA on a) TERT 
mRNA and protein expression was assessed. C2C12 cells were transfected with 100 
nM TERT siRNA and random siRNA (as control) and analysed 24 h after transfection. 
Reverse transcription PCR (RT-PCR) was performed on RNA extracted from treated 
cells. GAPDH mRNA was used as an internal control and an image of the gel was 
captured and used to quantify TERT mRNA expression using ImageJ software. 
Western blotting was performed to analyse TERT protein expression and β-actin was 
used as a loading control. b) The effect of TERT knock-down on 2-deoxyglucose 
uptake was assessed; cells were transfected with 100 nM TERT siRNA. Random 
siRNA was used as a negative control and cells were analysed 24 h after transfection. 
Cells were incubated in serum free medium for 4 h and 2-deoxyglucose uptake was 
measured over 10 min and is represented as pmol/10 min/mg protein. c) The effect of 
100 nM TERT siRNA, random siRNA and transfection reagent (Lipofectamine) on cell 
viability was assessed using MTT assay. d) Reverse transcription PCR (RT-PCR)was 
performed on RNA extracted fromC2C12 cells treated with 100 nM TETA, 
geldanamycin or 17-AAG for 24 h. GAPDH mRNA was used as an internal control and 
an image of the gel was captured and used to quantify TERT mRNA expression using 
ImageJ software. Values are means (±SEM) for 5 separate experiments, performed in 
duplicate. Asterisks indicate statistical significance (t-test) of difference from control: 
*p ≤ 0.05, **p b 0.01 and ***p b 0.001. 
 
Fig. 5. Effect of TERT over-expression on [3H] 2-deoxyglucose uptake in C2C12 cells. 
The effect of TERT over-expression on 2-deoxyglucose uptake was assessed; C2C12 
cells were transfected with pBABE-puro-TERT plasmid (6 μg). Lipofectamine and 
empty pBABE-puro plasmid (control vector) were used as negative controls. After 24 
h the cells were incubated in serum free medium for 4 h and 2-deoxyglucose uptake 
was measured over 10 min. 2-Deoxyglucose uptake is represented as pmol/10 min/mg 
protein. Values presented are means (±SEM) for 5 separate experiments, performed 
in duplicate. Asterisk indicates statistical significance (t-test) of difference from control: 
*p ≤ 0.05 
 
Fig. 6. Effect of TERT inhibition in C2C12 cells and over-expression and knock-down 
on [3H] 2-deoxyglucose uptake in human and primary mouse skeletal muscle cells. 
The effect of TERT inhibition on 2-deoxyglucose uptake was assessed in: a) C2C12 
cells treated with 100 nM geldanamycin (GA), TETA or 17-AAG for 24 h and then 100 
nM insulin for 10 min. b)Human and primary mouse skeletal muscle cells were 
transfected with 4 μg and 6 μg pBABE-puro-TERT plasmid, respectively. 
Lipofectamine and empty pBABE-puro plasmid (control vector) were used as negative 
controls. c) Next the effect of TERT knock-down on 2-deoxyglucose was assessed. 
Primary mouse and human skeletal muscle cells were transfected with 100 nM TERT 
siRNA and random siRNA was used as a negative control. After 24 h the cells were 
incubated in serum free medium for 4 h and 2-deoxyglucose uptake was measured 
over 10min. 2-Deoxyglucose uptake is represented as pmol/10 min/mg protein. Values 
are means (±SEM) for 4 independent experiments, performed in duplicate. Asterisks 
indicate statistical significance (t-test) of difference from control: *p ≤ 0.05 and **p b 
0.01. 
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